Gene Mack - 09 Aug 2024 Form 4 Insider Report for Gain Therapeutics, Inc. (GANX)

Role: CFO and Interim CEO
Signature: /s/ Gene Mack
Issuer symbol: GANX
Transactions as of: 09 Aug 2024
Transactions value $: $14,544
Form type: 4
Filing time: 12 Aug 2024, 17:23:31 UTC
Previous filing: 08 Apr 2024
Next filing: 07 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	GANX	Common Stock	Purchase	$14,544	+14,400		$1.01	14,400	09 Aug 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.98 to $1.07 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.

Content

The price reported in Column 4 is a weighted average price. These shares were bought in multiple transactions at prices ranging from $0.98 to $1.07 per share, inclusive. The reporting person undertakes to provide to Gain Therapeutics, Inc., any security holder of Gain Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein.